Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | PLAT | P00750 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10035051 | 0.80 | MCHR1 (0.49) | STAT3KLK7MAPTPOLBPLAU | |
| SCHEMBL10035032 | 0.80 | MAPT (0.49) | STAT3KLK7KDM4ESMN1; SMN2MAPT | |
| SCHEMBL10035266 | 0.79 | MCHR1 (0.49) | STAT3KLK7MAPTPOLBPLAU | |
| SCHEMBL10035061 | 0.78 | F10 (0.47) | STAT3KLK7GAASMN1; SMN2MAPT | |
| SCHEMBL10035033 | 0.77 | NPC1 (0.47) | STAT3KLK7KDM4EALDH1A1MAPT | |
| SCHEMBL10035265 | 0.76 | HTR1D (0.52) | STAT3KLK7KDM4EALDH1A1MAPK1 | |
| SCHEMBL10035001 | 0.75 | STAT3 (0.55) | STAT3KLK7ALDH1A1GAAMAPK1 | |
| SCHEMBL10035062 | 0.75 | ABCB1 (0.55) | STAT3KLK7ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL14930255 | 0.73 | STAT3 (0.53) | STAT3KLK7ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL10034976 | 0.73 | S1PR1 (0.47) | STAT3KLK7KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116227-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-05-09 | — | — | US | disclosed |
| WO-2012008435-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 大日本住友製薬株式会社 (JP) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116227-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | MC2R, NR3C2, REN | STAT3 690/4885KLK7 2190/4885KDM4E 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.